Becton Dickinson — May 1, 2025 release

As we take decisive mitigation actions to navigate the current macro environment, BD’s scale as the largest U.S. manufacturer of medical devices is a significant advantage for long-term value creation.” Recent Business Highlights • The company announces its intention to invest $2.5 billion in U.S. manufacturing capacity over the next 5 years, further strengthening its position as the largest U.S. manufacturer of medical devices and its commitment to ensuring a resilient U.S. health care system. • BD Medical: • The Medication Management Solutions business unit announced the BD Pyxis™ MedStation ES was honored with the 2025 Best in KLAS award for Automated Dispensing Cabinets and the BD Alaris™ Infusion System was honored in the Smart Pumps – Traditional category. This recognition underscores BD’s market leadership and dedication to safety and innovation across the entire medication use process. • The Advanced Patient Monitoring business unit launched its next generation hemodynamic monitoring solution, HemoSphere Alta™ Advanced Monitoring Platform , providing clinicians with AI-driven clinical decision support. • BD Interventional: • The Surgery business unit announced: Page 1 ◦ FDA 510(k) clearance and the launch of its Phasix™ ST Umbilical Hernia Patch , the industry's first bioabsorbable mesh designed specifically for umbilical hernia repair. ◦ A milestone in its clinical trial for the use of bioabsorbable GalaFLEX LITE™ Scaffold in breast implant revision surgery